Novavax rises after better-than-expected quarterly revenue

** Shares of vaccine maker Novavax NVAX.O rise 16.34% to $7.83

** Co reports Q2 revenue of $239 million vs analysts' estimate of $147.96 million

** Says received a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine

** For the full year, co now expects adjusted total revenue to be between $1 billion and $1.05 billion, compared to prior expectations of $975 million and $1.03 billion

** Q2 net income was $106.5 million, down from $162.4 million a year ago

** Co on a conference call says it continues to work with the U.S. Department of Health and Human Services' unit - Biomedical Advanced Research and Development Authority - on potential funding for its experimental bird flu vaccine

** Stock down ~2% YTD